Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.
about
Tumor-Derived Cell Lines as Molecular Models of Cancer PharmacogenomicsTargeting insulin and insulin-like growth factor signaling in breast cancerCooperating transcription factors mediate the function of estrogen receptorTherapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis.A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression.Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.Insulin-like growth factor receptor inhibitors: baby or the bathwater?ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cellsMultivariate hypergeometric similarity measure.Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry.Minireview: Were the IGF Signaling Inhibitors All Bad?A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells.Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines.Translational opportunities for broad-spectrum natural phytochemicals and targeted agent combinations in breast cancer.Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds.Dynamics of IGF-1R expression during endocrine breast cancer treatment.Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.Clinico-pathological Features of Mutation in HER2-Positive Breast Cancer of Indian Population
P2860
Q26801410-54AA0038-C9BF-499D-9F0C-C1891ED0185CQ26826380-529B5B1B-9C40-4417-B38A-49B9017FFF1BQ26996464-6CBB1590-1BD4-4510-AA5D-19F447A844ABQ33648503-763C951C-4E2B-4DE8-A7D2-3A01BB517695Q34112879-76C2AC37-FD79-4580-A0B9-4329C4B88F51Q34324699-F02A7C71-0147-46A6-85EB-4C36A2A5F3D5Q35037251-E6CF87AF-E8B8-4830-A500-B36B1238B208Q35100621-A16BB04E-2063-47FA-A0A0-FF1339DFB72FQ35609517-7C2DC727-E31E-4A45-8CCE-28BAE3F9C406Q35876634-3C62D87F-21F8-4C9D-B801-BF5A86A18EE9Q35903979-B625527B-6AC3-4048-85A6-B9F8BEF3CDB2Q36279700-984F830C-7F99-45AC-A975-14A3DA4406F5Q36642923-ABD7A9F3-7EEF-4582-A37D-20D0939AE646Q36790586-E5CB476E-9387-4851-807F-5D6DCCAFA372Q37013898-D4DFBA85-9848-4DF8-8F96-B4FAD29AA277Q37171068-132B49D0-828D-420F-86E4-D2A0A291D823Q37172268-0EC499FF-69D1-4F0C-8B9D-2DF453230ADDQ37690245-C9E8B124-0B96-4F6C-BA20-68C86F7BC225Q38403294-78D66F4D-3552-4B4A-970B-E9C6958C4E43Q38586367-07EFBB1D-EE05-4E53-9AEE-60C57BC76EFBQ38943401-C85AE9CF-F985-481C-8DD3-239433E19D88Q38952182-56B6ECB5-7885-4F2D-AACE-8EA61559DDF9Q39016042-C28CF684-938D-464C-B170-35E2C712D3D4Q42364417-E1CAFCA5-5E7C-47F1-BC20-26E2CA61C0C2Q47567895-96E5E5A0-6E2C-4A5F-BA24-48617A6109CAQ50890602-53E2E36B-A3AD-41F4-8BB0-20C1C71A7333Q51752849-4BDA0284-19D9-4059-A919-5299552B1A40Q55479657-1DE145E8-DA4B-40B6-859F-E54C271A07F4Q57106943-864759A9-443E-4B34-B5C2-A7505F66B137
P2860
Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Changes in breast cancer bioma ...... cer after tamoxifen treatment.
@en
Changes in breast cancer bioma ...... cer after tamoxifen treatment.
@nl
type
label
Changes in breast cancer bioma ...... cer after tamoxifen treatment.
@en
Changes in breast cancer bioma ...... cer after tamoxifen treatment.
@nl
prefLabel
Changes in breast cancer bioma ...... cer after tamoxifen treatment.
@en
Changes in breast cancer bioma ...... cer after tamoxifen treatment.
@nl
P2093
P356
P1476
Changes in breast cancer bioma ...... ncer after tamoxifen treatment
@en
P2093
J Reis-Filho
S Arbogast
S Johnston
V Barbashina
P304
P356
10.1530/ERC-10-0046
P577
2011-08-30T00:00:00Z